Life Sciences Tools & Services
Revvity's Q2 FY2026 performance reflected a $16.2 million tariff refund that boosted gross margin, but higher restructuring costs and a decline in Life Sciences software revenue led to a 1.6% dip in operating income.
Key risk: Government Funding and Economic Policy Uncertainty
Changes in U.S. funding priorities, trade policies, and regulatory environments have created a more cautious spending environment for healthcare and research customers, potentially reducing demand for Revvity's products. Budget cuts or freezes could further pressure sales.
Other Health Care Equipment companies